Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in inclusion body myositis (IBM), titled “Highly Differentiated Cytotoxic T Cells in Inclusion Body Myositis”. IBM is an autoimmune disease characterized by T cell infiltration and attack … Read More
abcuro
the next generation of T cell targeted bio-therapeutics
HOW IT WORKS
We take a patient-centric approach to identify dysfunctional immune pathways, validate their role in disease and discover new therapies to modulate their function.
LATEST NEWS
Abcuro Founder Reports on the Role of KLRG1+ T cells in Primary Billiary Cholangitis
Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in primary biliary cholangitis (PBC), titled “Cytotoxic KLRG1 Expressing Lymphocytes Invade Portal Tracts in Primary Biliary Cholangitis”. PBC is an autoimmune disease characterized by T cell … Read More